Senthil Selvaraj, Brian Claggett, Svati H Shah, Robert J Mentz, Michel G Khouri, Ani W Manichaikul, Sadiya S Khan, Stephen S Rich, Thomas H Mosley, Emily B Levitan, Pankaj Arora, Parag Goyal, Bernhard Haring, Charles B Eaton, Richard K Cheng, Gretchen L Wells, JoAnn E Manson, Marianna Fontana, Scott D Solomon
IMPORTANCE: Individual cohort studies concur that the amyloidogenic V142I variant of the transthyretin (TTR) gene, present in 3% to 4% of US Black individuals, increases heart failure (HF) and mortality risk. Precisely defining carrier risk across relevant clinical outcomes and estimating population burden of disease are important given established and emerging targeted treatments. OBJECTIVES: To better define the natural history of disease in carriers across mid to late life, assess variant modifiers, and estimate cardiovascular burden to the US population...
May 12, 2024: JAMA